If you’ve ever taken Zantac for heartburn, you probably didn’t expect it to be at the center of thousands of lawsuits. The controversy began when NDMA (N-Nitrosodimethylamine), a chemical linked to cancer, was discovered in the medication. This finding has ignited an ongoing legal battle. In this article, Ethen Ostroff Law explains what the Zantac lawsuit is all about, breaks down what NDMA is, updates you on the latest developments in the lawsuits, and provide the most recent news for 2025.
Zantac was the go-to remedy for heartburn and acid reflux for decades. It quickly became a familiar name in medicine cabinets since it hit the market in the 1980s. The key ingredient, ranitidine, is part of a group of drugs known as H2 blockers. They work by cutting down on stomach acid, which can be a real game-changer for those struggling with digestive problems.
At its height, Zantac was incredibly popular. It was the 50th most prescribed drug in the U.S., with over 15 million prescriptions each year. Developed by the European company GlaxoSmithKline and approved in the U.S. in 1983, Zantac’s success was fueled by a big marketing push
Zantac was a popular choice for managing various digestive issues. Here’s where it was commonly used:
Zantac has been produced by several major pharmaceutical companies. The key manufacturers are:
NDMA is a chemical that can be harmful and is known to increase cancer risk. It was found in Zantac at dangerously high levels. NDMA isn’t added to medicines intentionally. It forms when ranitidine, Zantac’s main ingredient, breaks down, especially in high temperatures. Studies showed that NDMA levels in Zantac were much higher than the FDA’s safety limit. This led to a major recall of Zantac products in 2019. The FDA found that long-term exposure to high levels of NDMA could raise the risk of several types of cancer.
Zantac has been linked to several health problems, mostly because of NDMA, a chemical that might cause cancer. Here are some of the main issues:
On April 1, 2020, the FDA asked all manufacturers to pull Zantac and its generic versions from the market. The reason? They discovered NDMA, a chemical that could be dangerous and potentially cause cancer, in these medications. Here’s what you should know:
The recall was a crucial step to protect health, and finding alternative medications is key for anyone affected.
The Zantac lawsuit began when it was found that ranitidine, the main ingredient in Zantac, could break down into NDMA—a chemical linked to cancer. This discovery led many former Zantac users who developed cancer to file lawsuits. In February 2020, these cases were combined into a multidistrict litigation (MDL) called In re: Zantac (Ranitidine) Products Liability Litigation. It’s overseen by Judge Robin L. Rosenberg in the Southern District of Florida. By July 2024, about 2,422 cases were still active. The MDL is still unfolding, with new developments, dismissals, and appeals as those affected pursue justice.
In the ongoing Zantac lawsuits, plaintiffs have made several allegations against the drug’s makers. These claims are central to the legal battle as those affected seek justice:
In the Zantac lawsuits, several pharmaceutical companies are being sued over the cancer risks linked to the drug. The main companies involved are:
As of 2024, the Zantac MDL is still ongoing. Here are some key updates:
August 7, 2024: An Illinois judge declared a mistrial in a case involving allegations that Zantac caused prostate cancer, as the jury was unable to reach a unanimous decision.
August 5, 2024: In Illinois, a jury determined that GSK was not liable for a plaintiff’s colorectal cancer, signaling challenges for similar claims despite ongoing litigation.
July 28, 2024: A settlement was finalized in a prostate cancer case against GSK in Illinois, marking a notable resolution in the ongoing Zantac litigation.
July 20, 2024: Two significant Zantac trials are currently in progress: one involving colorectal cancer and another focusing on prostate cancer, with settlement discussions ongoing.
July 19, 2024: New Zantac trials have started, including a colorectal cancer case and a prostate cancer case, with a recent settlement involving GSK but not Boehringer Ingelheim.
July 18, 2024: A state court trial against GSK and Boehringer Ingelheim has commenced, addressing colorectal cancer claims previously not covered by the MDL.
July 11, 2024: Plaintiffs in the Zantac mass tort case in Philadelphia have requested Judge Joshua Roberts’ recusal due to his wife’s connection with a law firm representing GSK.
July 5, 2024: A new lawsuit has been filed in Delaware accusing Zantac manufacturers of causing severe cancers due to NDMA contamination, with plaintiffs seeking damages for their health issues.
July 2, 2024: GSK has reached a confidential settlement in a prostate cancer lawsuit, adding to the list of resolved Zantac cases.
July 1, 2024: The number of active cases in the Zantac MDL has decreased significantly, shifting focus to state court litigations, especially in Delaware and California.
June 3, 2024: A Delaware judge has mandated that Zantac-related cases be tried in state courts, impacting around 75,000 lawsuits involving major pharmaceutical companies.
May 28, 2024: Zantac jury trials are scheduled in Chicago throughout 2024 and early 2025, with additional trials set for Philadelphia.
May 24, 2024: A Chicago jury found that Zantac was not responsible for a woman’s colon cancer, emphasizing the difficulty in proving such cases.
May 23, 2024: In a Chicago trial, the plaintiff’s attorneys requested $640 million from Zantac manufacturers, highlighting the stakes involved in these cases.
May 19, 2024: A whistleblower lawsuit has been filed against GSK, alleging that the company hid Zantac’s cancer risks, potentially leading to significant financial repercussions.
May 10, 2024: An 89-year-old woman diagnosed with colon cancer in 2015 after using Zantac for nearly 20 years is the latest plaintiff in the ongoing trials.
May 8, 2024: Pfizer has settled over 10,000 Zantac lawsuits, surpassing Sanofi’s recent settlement, with ongoing trials and the potential for more settlements.
May 2, 2024: Angela Valadez’s lawsuit against GSK and Boehringer Ingelheim over Zantac-related colorectal cancer has begun, with a settlement anticipated.
April 22, 2024: Bloomberg reports that recent Zantac settlements averaged around $25,000 per case, significantly lower than initial estimates.
April 4, 2024: Sanofi has settled approximately 4,000 Zantac lawsuits outside Delaware, with specific settlement terms remaining undisclosed.
February 29, 2024: GSK has reached a confidential settlement in a California Zantac lawsuit, opting for a settlement to avoid trial disruptions.
February 2, 2024: GSK settled another Zantac lawsuit before trial, resolving the case with David Browne.
February 1, 2024: Lawyers express cautious optimism about the upcoming ruling by Judge Medinilla, which could impact the future of Zantac litigation.
January 25, 2024: The Daubert hearing in Delaware has concluded, with Judge Vivian L. Medinilla expected to make significant decisions regarding the litigation’s future.
January 23, 2024: The Daubert hearing in Delaware continues, with important implications for the Zantac litigation’s trajectory.
January 19, 2024: The upcoming Daubert hearings in Delaware are set to be crucial for the future of Zantac litigation.
January 14, 2024: An appeal in the Zantac MDL is crucial for the 14,389 plaintiffs, potentially shifting claims to state courts.
On August 7, 2024, the third trial related to Zantac ended in a mistrial. Jurors couldn’t decide if Boehringer Ingelheim was to blame for an Illinois man’s cancer. Martin Gross claimed that NDMA, a harmful chemical in Zantac, caused his prostate cancer. His lawyer plans to retry the case. Boehringer Ingelheim, however, says the evidence shows Zantac doesn’t cause cancer. This mistrial follows two earlier cases, where both ended with decisions in favor of the defense—one for Boehringer Ingelheim and GSK, and one just for GSK. Most Zantac lawsuits are happening in Delaware. In June, a judge allowed over 70,000 cases to proceed, despite the defendants’ attempt to exclude key expert witnesses. The companies are appealing this decision.
If you’re considering joining a Zantac lawsuit, here’s a simple breakdown of who might be eligible:
Regular Use: You need to have taken Zantac (Ranitidine) regularly for at least a year before your cancer diagnosis.
Dosage: Typically, this means using at least 300 mg per week, which generally translates to at least once a week.
Time Frame: You should have used Zantac, whether by prescription or over the counter, between 1984 and 2020.
Age at Diagnosis: You must have been diagnosed with a qualifying cancer at 70 years old or younger.
Timing: Your cancer diagnosis should have occurred after 2022, or within 10 years of your last use of Zantac.
You may qualify if you’ve been diagnosed with one of the following cancers, and meet these additional criteria:
Bladder Cancer: No family history and no catheter use before diagnosis.
Breast Cancer: Only ductal carcinoma qualifies (excludes BRCA1 or BRCA2 mutations).
Colorectal Cancer: No family history or Crohn’s disease before starting Zantac.
Esophageal Cancer: No smoking 25 years before diagnosis and no Barrett’s esophagus before using Zantac.
Lung Cancer: No family history or smoking 25 years before diagnosis.
Liver Cancer: No hepatitis B or C, or Wilson’s disease before or after using Zantac, and no family history.
Pancreatic Cancer: No family history.
Prostate Cancer: No family history and diagnosed at 70 years old or younger.
Stomach/Gastric Cancer: No family history.
You won’t qualify if:
Generic Use Only: You only used generic ranitidine.
Location: You were a resident of Michigan, Tennessee, Louisiana, Kentucky, or Puerto Rico at the time of use or diagnosis.
If you meet these criteria, you might be eligible to pursue a claim.
If you believe you may be eligible for a Zantac claim, consider the following steps:
If you win or settle a Zantac lawsuit, you might receive compensation for:
These funds are meant to cover the various ways Zantac has affected your life.
The Zantac lawsuit has been a turbulent journey. If you’re dealing with a cancer diagnosis linked to Zantac, we can help you. At Ethen Ostroff Law, we’re deeply engaged in these cases and ready to guide you through the process. Let’s help you pursue the justice and compensation you deserve. Contact us today for Zantac update and the support you need.
Some Zantac lawsuits have been settled, with Sanofi agreeing to pay up to $250 million in 2024 and GSK settling several cases confidentially. However, major settlements for other cases might not happen until late 2024 or beyond.
The average payout for Zantac lawsuits isn’t clear yet. Serious cases might exceed $500,000, mid-range cases could be around $250,000, and lower-tier cases might fall between $20,000 and $160,000. A recent $500,000 settlement provides some insight, but the overall average will solidify as more cases are settled.
Yes, the Zantac lawsuit is still active. Thousands of claims are ongoing, and legal proceedings are continuing to address these cases.
To support a Zantac lawsuit, you’ll need to provide medical records showing a cancer diagnosis and evidence of long-term Zantac use.
No, Zantac isn’t safe to take due to its potential NDMA content, a known carcinogen. Consult with your healthcare provider for alternative treatments.
Yes, there are current Zantac class action lawsuits against the manufacturers. These cases are centered on the claim that Zantac contains NDMA, a carcinogen.
Nicholas began his post-graduate career clerking for the Honorable Linda Rovder Fleming in the Cambria County Court of Common Pleas. From there, he quickly found his calling in workers’ compensation, personal injury, and Social Security disability law—areas where he could directly impact people’s lives in moments of crisis. He’s helped clients navigate complex legal claims, including securing a settlement exceeding $300,000.
Nicholas brings clear communication, genuine empathy, and an unrelenting drive to achieve the best outcomes for his clients. Whether he’s navigating a complex workers’ comp claim or pushing for a major settlement, he brings focus, dedication, and deep legal knowledge to every case.
He’s also a proud member of Pennsylvania Advocates for Justice and remains active in various professional legal organizations. Nicholas is licensed to practice law in Pennsylvania.
When he’s not fighting for the injured, Nicholas is enjoying time with his family, kicking a soccer ball around, hitting the golf course, or cheering on Pittsburgh’s local teams.
Joe Ring heads the workers’ compensation department at Ethen Ostroff Law, where he takes pride in fighting for injured workers.
Joe is a Philadelphia native and maintains deep roots in the area. As the grandson of a Philadelphia Firefighter, son of a Philadelphia public school teacher, and veteran of the United State Marine Corps, he was taught to value service, dedication, and hard work. He applies these values to every case and takes great satisfaction in representing hard-working clients with those same traits.
After obtaining his bachelor’s degree in history from St. Vincent College in Western Pennsylvania, he graduated from Villanova Law School in 2012 and, since then, has litigated hundreds of workers’ compensation hearings and trial depositions on behalf of both employers and injured workers. During this time, Mr. Ring has written articles and presented Continuing Legal Education courses on developments in Pennsylvania Workers’ Compensation Law. He is active in local professional organizations, and, in 2022, he served a Co-chairperson of the Philadelphia Bar Associations Workers’ Compensation Section.
Since coming to EOL in 2024, he has dedicated his practice entirely to helping injured workers navigate the system and obtain their rightful benefits.
Joe is licensed to practice in Pennsylvania.
Brandon Zanan heads the personal injury claim department with Ethen Ostroff Law.
Brandon’s education in both law and medicine assist him in expertly representing badly injured victims. Brandon has a Master’s Degree in Forensic Medicine from the Philadelphia College of Osteopathic Medicine, with a concentration in anatomy and pathology. With this knowledge, Brandon is skilled at analyzing medical records and understanding injuries that are common in personal injury claims. He uses this expertise in conjunction with listening carefully to each client’s needs, in order to fiercely advocate for clients and tell their stories when they would not otherwise have a voice.
Brandon’s background includes a variety of experience and skills in various areas of civil practice. He is the author and editor of numerous books for the George T. Bisel Publishing Company, including “Pennsylvania Damages” and the “Pennsylvania Vehicle Code Annotated,” two texts that are frequently relied on by lawyers and judges across Pennsylvania as authoritative resources on personal injury law.
Brandon is a member of the Pennsylvania and Montgomery Bar Associations. He is also a member of Pennsylvania Association for Justice, and has served as an executive board member of the Montgomery American Inn of Court.
He is admitted to practice in the Commonwealth of Pennsylvania, the United States District Courts for the Eastern District of Pennsylvania and Middle District of Pennsylvania, the State of New Jersey, the United States District Court for the District of New Jersey, and in the Commonwealth of Virginia. Brandon has represented many clients in motor vehicle, premises liability, animal bite, and products liability cases across Pennsylvania and New Jersey and has obtained outstanding results with millions of dollars recovered for his clients.
He has been named a Pennsylvania Rising Star from 2021 onward. The “Super Lawyers-Rising Star®”, list recognizes no more than 2.5 percent of attorneys in each state
Brandon currently lives in Malvern with his wife Rachel and their son Max.
Effective Date: July 10, 2024
General Information
Welcome to the website of Ethen Ostroff Law, PLLC (“EO”). By accessing or using our website, you agree to be bound by these Terms and Conditions (“Terms”). If you do not agree with these Terms, please do not use our website.
Use
EO hereby grants you a non-exclusive, non-transferable, revocable, limited right and license to access and use the Site solely for your personal use in accordance with these Terms of Use. You shall not, in any way, otherwise copy, reproduce, distribute, transmit, display, perform, reproduce, publish, license, modify, create derivative works from, sell, or exploit the Site.
EO may at any time, for any reason, and without notice or liability: (a) modify, suspend, or terminate operation of or access to the Site and related services, or (b) change, revise, or modify the Site and affiliated services.
Messaging and Automated Calls
When you opt-in, you will receive text messages (SMS/MMS) on your mobile number. These messages may contain information about your case, and the message frequency may vary from user to user. Please note that message and data rates may apply. If you wish to opt out of this service, you can do so anytime by simply texting “STOP” to the phone number. Once you text “STOP” to us, we will send you an SMS to confirm that you have been unsubscribed. If you encounter any issues, you can reply with the keyword “HELP” to get assistance. Please be aware that carriers are not responsible for any delayed or undelivered messages.
By providing your phone number and submitting a form on our website, you consent to receive communications, including automated calls, texts, and pre-recorded messages, from EO and its affiliates. These communications may include updates about your case, promotional offers, and other information. You understand that these calls may be generated using automated technology, and that standard message and data rates may apply.
Your consent to receive automated calls is not a condition of any purchase or service. By checking the consent box on our contact form or by calling our firm, you agree to these Terms and Conditions and provide your written consent to receive these communications. You may opt out of these communications at any time by replying STOP to any text message or by contacting us at [insert contact information].
State-Specific Compliance
EO complies with all federal and state laws regarding automated calls and telemarketing practices. Certain states have additional restrictions on the use of automated dialing systems and pre-recorded messages. The following states have more restrictive regulations:
If you are a resident of one of these states, EO will obtain your prior express written consent before making any automated calls or sending pre-recorded messages to you.
By submitting a form inquiry or calling our firm, you agree to us contacting you, and your checking the box when submitting your form inquiry serves as written consent.
Information and Legal Disclaimer
The information contained in this website is for informational purposes only, and should not be construed as legal advice. Testimonials and case results contained in this website are for demonstrative purposes only, and do not constitute a guarantee of any particular outcome in a specific case.
By requesting a free consultation with Ethen Ostroff Law, PLLC, you agree to the following:
The law differs in every jurisdiction, and you should not rely on any opinion except that of an attorney you have retained, who has a professional duty to advise you after being fully informed of all the pertinent facts, and who is licensed in the applicable state, and is familiar with the applicable law. Internet subscribers, mobile application users, and online readers should seek professional counsel about their legal rights and remedies. You should not act or refrain from acting on the basis of any information found on the Site. Any actions or decisions about your legal rights should be based on the particular facts and circumstances of your situation, and appropriate legal advice from an attorney retained directly by you. EO EXPRESSLY DISCLAIMS ALL LIABILITY WITH RESPECT TO ACTIONS TAKEN OR NOT TAKEN BASED UPON ANY INFORMATION OR OTHER CONTENTS OF THIS SITE. Viewing the Site, or communicating with EO by Internet e-mail or through the Site does not constitute or create an attorney-client relationship with anyone. The content and features on the Site do not create, and are not intended to create, an attorney-client relationship, and shall not be construed as legal advice. The content and features of the Site, including means to submit a question or information, do not constitute an offer to represent you or otherwise give rise to an attorney/client relationship.
THE SITE IS PROVIDED “AS IS”. EO MAKES NO WARRANTIES, EXPRESS OR IMPLIED, REGARDING THE SITE AND ONLINE SERVICES AND HEREBY DISCLAIMS ALL WARRANTIES OF ANY KIND OR NATURE, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, AND NON-INFRINGEMENT. WITHOUT LIMITING THE FOREGOING, EO DOES NOT GUARANTEE THAT THE ONLINE SERVICES OR PRODUCTS WILL MEET YOUR REQUIREMENTS, OR WILL BE ERROR-FREE, UNINTERRUPTED, OR FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS, OR THAT ANY DEFECTS WILL BE CORRECTED.
Accounts
To use some features of the Site, you may be required to create an account. In connection therewith, you agree to provide and maintain true, accurate, current, and complete information about yourself. You are responsible for maintaining the confidentiality of the information you hold for your account login, including your password, and for all Submissions made from your account. You agree to notify us immediately of any unauthorized use of your login. EO may suspend access to your account if it suspects illegal or improper use, or for other reasons, such as for account management purposes, at its sole discretion.
Confidentiality is Not Guaranteed
Information sent to Ethen Ostroff Law, PLLC. via Internet e-mail or through the Site is not secure and is done on a non-confidential basis. EO may make reasonable efforts to keep communications private, but because of the nature of Internet communications and the absence of an attorney/client relationship, we cannot promise or guarantee confidentiality.
DISCLAIMER – This Site Does Not Provide Medical Diagnosis or Advice
The content provided on the Site, such as documents, text, graphics, images, videos, news alerts, pharmaceutical drug recalls, prescription medication history, or information on litigation concerning the foregoing topics, or other materials, is for informational purposes only. The information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always consult a physician for diagnosis and treatment of any medical condition or for any questions you may have regarding a health concern. Never disregard professional medical advice, alter a prescription plan in any way, or delay or refrain from seeking medical advice because of something you have read or seen on the Site. Links to other sites are provided for information only. Use of trade names is for identification only and does not constitute endorsement by EO.
Without limiting the generality of the foregoing, the Site may present information about pharmaceutical drug recalls, which is for information purposes only. Such information is not necessarily the most current information on the subject and may or may not be updated based on the last information concerning such recalls. Do not make any decisions regarding medication or medical providers based on information from the Site, including but not limited to information we provide about drug recalls.
EO Is Not Responsible for Content; Limitation on Liability
EO may periodically change, remove, or add the material on the Site without notice. This material may contain technical or typographical errors. EO DOES NOT GUARANTEE ITS ACCURACY, COMPLETENESS OR SUITABILITY. EO assumes no liability or responsibility for any errors or omissions in the contents of the Site. Your use of the Site is at your own risk. Under no circumstances shall EO or any other party involved in the creation, production, or delivery of the Site be liable to you or any other person for any indirect, special, incidental, or consequential damages of any kind arising from your access to, or use of, the Site. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW IN NO EVENT SHALL EO BE LIABLE FOR ANY SPECIAL, INDIRECT, OR CONSEQUENTIAL DAMAGES RELATING TO THIS MATERIAL, FOR ANY USE OF THIS WEBSITE, OR FOR ANY OTHER LINKED WEBSITE.
Third-party Web Sites
The Site contains links to third-party websites for the convenience of our users. EO does not endorse any of these third-party sites and does not imply any association between EO and those sites. EO does not control these third-party websites and cannot represent that their policies and practices will be consistent with these Terms of Use. If you use links to access and use such websites, you do so at your own risk. EO is not responsible for the contents or availability of any linked sites. These links are provided only as a convenience to the recipient. These Terms only apply to the Site and do not apply to any linked sites. We encourage you to read and understand the terms of use of any linked sites that you visit. Links do not imply that we sponsor, endorse, are affiliated with or associated with, or are legally authorized to use any trademark, trade name, service mark, design, logo, symbol, or other copyrighted materials displayed on or accessible through any linked site.
EO Clients
Only individuals who have entered into a mutually signed retainer agreement with EO are EO clients (“EO Clients”).
Legal and Ethical Requirements
EO has tried to comply with all legal and ethical requirements in compiling the Site. We welcome comments about our compliance with the applicable rules and will update the Site as warranted, upon learning of any new or different requirements.
Ethen Ostroff Law reserves the right to refer or sell leads that come through any of Ethen Ostroff Law’s marketing.
Ethen Ostroff Law also may sell leads on certain campaigns generated in association with third party marketing companies.
Governing Laws in Case of Dispute; Jurisdiction
These Terms of Use shall be governed by and construed in accordance with the laws of the State of Pennsylvania, USA, without regard to any choice of law principles. Any and all disputes arising hereunder shall be governed as set forth in the Arbitration section below.
Submissions
You are solely responsible for any information, content, or material you transmit to or through the Site (“Submissions”). You understand that Submissions are considered non-confidential and non-proprietary. Furthermore, you grant EO an unrestricted, irrevocable, perpetual, transferable, sublicensable, worldwide, royalty-free license to use, copy, reproduce, display, publish, publicly perform, transmit, and distribute any Submission, without compensation or accounting to you or anyone else. You represent and warrant that: (a) you have the right to submit the Submission to EO and grant the licenses as described above; (b) EO will not need to obtain licenses from any third party or pay royalties to any third party for its use of the Submission; (c) the Submission does not infringe any third party’s rights, including intellectual property rights and privacy rights; and (d) the Submission complies with these Terms of Use and all applicable laws and regulations.
EO takes no responsibility and assumes no liability for any Submission.
Arbitration
Any and all claims by you arising out of or related to the Site or your use thereof may be resolved only through a binding arbitration proceeding to be conducted under the auspices of the Commercial Arbitration Rules of the American Arbitration Association in Montgomery County, Pennsylvania. Both your agreement to arbitrate all controversies, disputes and claims, and the results and awards rendered through the arbitration, will be final and binding on you and may be specifically enforced by legal proceedings. Arbitration will be the sole means of resolving such controversies, disputes and claims, and you waive your rights to resolve such controversies, disputes and claims by court proceedings or any other means. You agree that judgment may be entered on the award in any court of competent jurisdiction and, therefore, any award rendered shall be binding. The arbitrator may not consolidate more than one person’s claims, and may not otherwise preside over any form of a representative or class proceeding. You understand that by agreeing to arbitration as a mechanism to resolve all controversies, disputes and claims between us, you are waiving certain rights, including the right to bring an action in court, the right to a jury trial, the right to broad discovery, and the right to an appeal. You understand that in the context of arbitration, a case is decided by an arbitrator (one or more), not by a judge or a jury.
International Use
The Site is controlled, operated, and administered by EO from offices within the United States of America and is only intended for use therein. We make no representation regarding use of the Site outside of the United States.
Other Terms
If, for any reason, our Terms of Use, Privacy Policy, or any portion thereof to be unenforceable, such provision shall be enforced to the maximum extent permissible so as to give the intended effect thereof, and the remainder of these Terms of Use and Privacy Policy shall continue in full force and effect. EO’s failure to act with respect to a breach by you or others does not waive our right to act with respect to that breach or subsequent or similar breaches. No consent or waiver by EO hereof will be deemed effective unless in writing. These Terms of Use, together with our Privacy Policy, as each is currently posted, constitute the entire agreement between EO and you with respect to your use of the Site and supersede all previous written or oral agreements relating to the subject matter hereof, that this agreement shall not supersede, restrict, or replace any agreements governing the attorney-client relationship between EO and EO Clients.
EO may, in its sole discretion and without prior notice, block and/or terminate your access to the Site and if we determine that you have violated these Terms of Use or other terms or agreements or that may be associated therewith or if you use the Site in a way that we deem, in our sole discretion, to be an unacceptable use.
